"Full Prescribing Information Emtriva (FTC)", 1 January 2012 (2012-01-01), Gilad Sciences, Inc, Foster City, CA 94404, USA (B1)

"Full Prescribing Information Viread (TDF)", 1 January 2012 (2012-01-01), Gilead Sciences, Inc, Foster City, CA 94404, USA (B1)

FOR THE UK COLLABORATIVE HIV COHORT (CHIC) STUDY PHILLIPS ET AL: "Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9603, 6 December 2007 (2007-12-06), pages 1923-1928, XP022379072, ISSN: 0140-6736 (B1)

GERMAN P ET AL: "pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single tablet fixed dose combination", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS,PHILADELPHIA, PA, US, vol. 55, no. 3, 1 November 2010 (2010-11-01), pages 323-329, XP008134624, ISSN: 1525-4135 (B1)

WO-A1-2008/103949 (B1)

L. SZCZECH: "Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context", THE JOURNAL OF INFECTIOUS DISEASES, vol. 197, no. 1, 2008, pages 7-9, XP002630507, (B1)

S. HAMMER ET AL.: "Antiretroviral treatment of adult HIV infection. 2008 Recommendations of the International AIDS Society- USA panel.", JAMA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 300, no. 5, 2008, pages 555-570, XP8134902, (B1)

US-B2- 7 176 220 (B1)

V. VON WYL ET AL.: "Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment", ARCHIVES OF INTERNAL MEDICINE, vol. 167, no. 16, 2007, pages 1782-1790, XP002630508, (B1)

J. MARTINEZ-CAJAS ET AL.: "Antiretroviral therapy- Optimal sequencing of therapy to avoid resistance", DRUGS, vol. 68, no. 1, 2008, pages 43-72, XP8134919, (B1)